Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
15.80
-0.26 (-1.65%)
At close: Mar 6, 2026, 4:00 PM EST
15.80
+0.01 (0.03%)
After-hours: Mar 6, 2026, 5:40 PM EST
Corvus Pharmaceuticals Employees
Corvus Pharmaceuticals had 31 employees as of December 31, 2024. The number of employees increased by 3 or 10.71% compared to the previous year.
Employees
31
Change (1Y)
3
Growth (1Y)
10.71%
Revenue / Employee
n/a
Profits / Employee
-$486,290
Market Cap
1.32B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 645 |
| Day One Biopharmaceuticals | 178 |
| EyePoint | 165 |
| Capricor Therapeutics | 160 |
| Monte Rosa Therapeutics | 147 |
| Zenas BioPharma | 130 |
| MoonLake Immunotherapeutics | 130 |
| ORIC Pharmaceuticals | 106 |
CRVS News
- 2 days ago - Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 - GlobeNewsWire
- 12 days ago - Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 6 weeks ago - Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M - GlobeNewsWire
- 6 weeks ago - Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock - GlobeNewsWire
- 6 weeks ago - Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon - Seeking Alpha
- 6 weeks ago - Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know - Seeking Alpha
- 6 weeks ago - Corvus Pharmaceuticals, Inc. (CRVS) Discusses Phase 1 Clinical Trial Results of Soquelitinib in Atopic Dermatitis with Focus on Cohort 4 Transcript - Seeking Alpha
- 6 weeks ago - Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire